Murepavadin
CAS No. 944252-63-5
Murepavadin( POL7080 | POL 7080 )
Catalog No. M16763 CAS No. 944252-63-5
Murepavadin (POL7080)?is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMurepavadin
-
NoteResearch use only, not for human use.
-
Brief DescriptionMurepavadin (POL7080)?is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.
-
DescriptionMurepavadin (POL7080)?is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.Bacterial Infection Phase 3 Clinical.
-
In VitroMurepavadin has activity against P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L.Murepavadin inhibits megalin-mediated uptake of gentamicin in vitro with an IC50 value of 5.84 μM.
-
In VivoMurepavadin (s.c.; 0-100 mg/kg) is active in pre-clinical animal models including infections with XDR isolates. Animal Model:murine models of P. aeruginosa infectionDosage:0-100 mg/kg Administration:Subcutaneous, q24h or q12h Result:Resulted in an increase in survival rate to 100% and showed significantly lower CFU levels both in the blood and in the peritoneal fluid at 2 and 10 mg/kg 1 h post-infection.Animal Model:Mouse, rat, rabbit, and monkey Dosage:0-5 mg/kg Administration:Intraperitoneal or subcutaneous, single Result:Followed a two-compartment model following intravenous administration and decline of plasma concentrations.Distributed into the aqueous phase of the body, and systemic plasma clearance (CL) values were similar to the species-specific glomerular filtration rates (GFRs) .Had high bioavailability (67.79%) after subcutaneous (s.c.) administration in rats but had low oral bioavailability (<0.01%).Had a linear relationship between ELF AUC and unbound plasma AUC in mouse.
-
SynonymsPOL7080 | POL 7080
-
PathwayGPCR/G Protein
-
TargetAntibacterial
-
RecptorAntibacterial
-
Research AreaInfection
-
IndicationBacterial Infection
Chemical Information
-
CAS Number944252-63-5
-
Formula Weight1553.837
-
Molecular FormulaC73H112N22O16
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)N3CCCC3C(=O)NC(C(=O)NC(C(=O)N1)CC4=CNC5=CC=CC=C54)C(C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN
-
Chemical Namecyclo[Ala-Ser-D-Pro-Pro-Thr-Trp-Ile-Dab-Orn-D-Dab-Dab-Trp-Dab-Dab]
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bassetti M, et al. Curr Opin Infect Dis. 2018 Jan 13. doi: 10.1097/QCO.0000000000000438.
molnova catalog
related products
-
Demethoxyencecalin
Demethoxyencecalin is extracted from Helianthus annuus with antifungal activities.
-
Pachybasin
Pachybasin is an anthraquinone fungal metabolite. Pachybasin shows antimicrobial activities against E. coli, B. subtilis, M. luteus, S. cerevisiae, C. albicans, A. niger, and A. flavus, with MIC values of 64.0 μg/mL, and against S. aureus and F. oxysporum with MIC values of 32.0 and 16.0 μg/mL respectively.
-
MAC168425
MAC168425 is a novel antibacterial inhibitor that interferes with glycine metabolism in E coli.